- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.01. | Sera Prognostics: Positive Studiendaten zu Frühgeburtentest beflügeln Aktie | 1 | Investing.com Deutsch | ||
| 07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 15.12.25 | Jefferies initiates Sera Prognostics stock with Buy rating on preterm birth test | 1 | Investing.com | ||
| 15.12.25 | Jefferies stuft Sera Prognostics mit "Buy" ein - Frühgeburtentest als Kurstreiber | 3 | Investing.com Deutsch | ||
| 14.11.25 | Sera Prognostics outlines accelerated Medicaid pilot expansion to 13 states as commercialization momentum builds | 1 | Seeking Alpha | ||
| 13.11.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2025 Financial Results | 756 | PR Newswire | SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 13.11.25 | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.10.25 | Sera Prognostics Appoints Tiffany Inglis As CMO | - | RTTNews | ||
| 01.10.25 | Sera Prognostics appoints Dr. Tiffany Inglis as chief medical officer | 1 | Investing.com | ||
| 01.10.25 | Sera Prognostics, Inc.: Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer | 150 | PR Newswire | SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
| 05.09.25 | SERA PROGNOSTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.09.25 | Sera Prognostics forciert Kommerzialisierung des PreTRM-Tests | 1 | Investing.com Deutsch | ||
| 06.08.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2025 Financial Results | 123 | PR Newswire | SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 08.05.25 | Sera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial Officer | 292 | PR Newswire | Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company®... ► Artikel lesen | |
| 07.05.25 | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial Results | 371 | PR Newswire | SALT LAKE CITY, May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by... ► Artikel lesen | |
| 19.03.25 | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 277 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,525 | -2,56 % | NanoRepro zündet die nächste Story: Mit PHLAS startet der Sprung ins Premium-SkinTech-Geschäft | NanoRepro geht den nächsten strategischen Schritt - und der hat mit klassischen Selbsttests nur noch am Rand zu tun: Mit dem offiziellen Marktstart des Kaltplasmageräts "PHLAS" und dem Livegang des... ► Artikel lesen | |
| OCUGEN | 1,600 | +4,20 % | Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa | Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,470 | -0,73 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| COSCIENS BIOPHARMA | 1,560 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| BIOCRYST PHARMACEUTICALS | 7,358 | -0,70 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| IBIO | 2,120 | -11,67 % | iBio, Inc. - 8-K, Current Report | ||
| VAXART | 0,600 | -4,76 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,740 | -5,32 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,970 | -1,02 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| CARDIFF ONCOLOGY | 1,496 | -8,67 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update | Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of... ► Artikel lesen | |
| MANNKIND | 2,588 | -6,60 % | H.C. Wainwright cuts MannKind stock price target on Tyvaso outlook | ||
| ALDEYRA | 4,606 | -0,41 % | Aldeyra Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TRAWS PHARMA | 1,670 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal ... | Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID- with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,358 | -4,23 % | Coherus Oncology, Inc.: Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,295 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.